The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis

Authors :: Takeshi Hatanaka
Atsushi Naganuma
Atsushi Hiraoka
Toshifumi Tada
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Chikara Ogawa
Takashi Nishimura
Noritomo Shimada
Kazuhito Kawata
Hisashi Kosaka
Satoru Kakizaki
Takaaki Tanaka
Hideko Ohama
Kazuhiro Nouso
Asahiro Morishita
Akemi Tsutsui
Takuya Nagano
Norio Itokawa
Tomomi Okubo
Taeang Arai
Michitaka Imai
Yohei Koizumi
Shinichiro Nakamura
Masaki Kaibori
Hiroko Iijima
Yoichi Hiasa
Takashi Kumada
the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Source :: Cancer Medicine, Vol 12, Iss 4, Pp 4259-4269 (2023)
Publication Year :: 2023
Publisher :: Wiley, 2023.
Abstract: Abstract Aim This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). Methods A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (

Subjects :: aspartate transaminase‐to‐alanine transaminase ratio
atezolizumab and bevacizumab
HCC‐GRIm score
hepatocellular carcinoma
lactate dehydrogenase
neutrophil‐to‐lymphocyte ratio
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools